Cookson Peirce & Co. Inc. Sells 83 Shares of argenx SE (NASDAQ:ARGX)

Cookson Peirce & Co. Inc. lowered its stake in argenx SE (NASDAQ:ARGX) by 0.4% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 23,483 shares of the company’s stock after selling 83 shares during the quarter. Cookson Peirce & Co. Inc.’s holdings in argenx were worth $14,442,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in the stock. FMR LLC boosted its holdings in shares of argenx by 35.9% during the 3rd quarter. FMR LLC now owns 4,793,472 shares of the company’s stock valued at $2,598,445,000 after acquiring an additional 1,265,486 shares in the last quarter. Lord Abbett & CO. LLC bought a new position in argenx in the third quarter valued at about $88,339,000. Allspring Global Investments Holdings LLC boosted its stake in shares of argenx by 38,152.3% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 144,211 shares of the company’s stock valued at $89,391,000 after purchasing an additional 143,834 shares in the last quarter. Jennison Associates LLC grew its holdings in shares of argenx by 27.0% during the fourth quarter. Jennison Associates LLC now owns 302,149 shares of the company’s stock worth $185,821,000 after purchasing an additional 64,183 shares during the last quarter. Finally, Wellington Management Group LLP increased its stake in shares of argenx by 13.0% in the third quarter. Wellington Management Group LLP now owns 482,346 shares of the company’s stock valued at $261,470,000 after buying an additional 55,617 shares during the period. 60.32% of the stock is currently owned by institutional investors and hedge funds.

argenx Trading Down 0.2 %

Shares of NASDAQ ARGX opened at $621.25 on Wednesday. The firm has a market capitalization of $37.75 billion, a P/E ratio of -705.97 and a beta of 0.58. The firm’s 50-day moving average price is $642.51 and its 200-day moving average price is $591.91. argenx SE has a 1-year low of $349.86 and a 1-year high of $678.21.

argenx (NASDAQ:ARGX) last posted its quarterly earnings results on Thursday, February 27th. The company reported $1.58 earnings per share for the quarter, topping analysts’ consensus estimates of $0.98 by $0.60. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. The business had revenue of $761.22 million for the quarter, compared to the consensus estimate of $678.52 million. Equities research analysts forecast that argenx SE will post 3.13 EPS for the current year.

Analyst Upgrades and Downgrades

Several research firms recently commented on ARGX. Deutsche Bank Aktiengesellschaft downgraded shares of argenx from a “hold” rating to a “sell” rating in a research report on Friday, January 17th. Evercore ISI lifted their price target on shares of argenx from $675.00 to $706.00 and gave the stock an “outperform” rating in a report on Thursday, November 21st. JMP Securities increased their price objective on argenx from $606.00 to $696.00 and gave the company a “market outperform” rating in a report on Tuesday, January 14th. Oppenheimer lifted their target price on argenx from $675.00 to $704.00 and gave the stock an “outperform” rating in a report on Friday, February 28th. Finally, Truist Financial reissued a “buy” rating and issued a $700.00 price target (up previously from $660.00) on shares of argenx in a research note on Tuesday, January 14th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, eighteen have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $662.83.

argenx Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.